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Poster Session I S217to the DNA replicative, recombination and repair and nucleic acid
metabolism pathways. Hierarchical clustering analysis of 347 dif-
ferentially expressed cell cycle and apoptosis genes again separated
the early and late passage cells into two groups and a node of genes
up-regulated in late passages cells included two genes involved with
replication senescence, cyclin-dependent kinase inhibitor 1A (p21,
Cip1) (CDKN1A) and cyclin-dependent kinase inhibitor 2A (mel-
anoma, p16, inhibits CDK4) (CDKN2A) and one that inhibits
TRAIL mediated apoptosis, tumor necrosis factor receptor super-
family, member 10d (TNFRSF10D, DCR2, CD264). Flow cytom-
etry analysis confirmed greater expression of TNFRS10D on late
passage cells. BMSC senescence is associated with distinct molecu-
lar changes. Early passage BMSCs may have more immune modu-
latory properties.172
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Introduction: Allogeneic stem cell transplantation (allo-SCT) is
hampered by GvHD, infections like CMV and relapse of disease.
Gammadelta T-cells (gdT-cells) seem to be important in virus con-
trol but also in malignancy control. CMV infections are associated
with an increased expansion of Vd11T cells. Therefore, we investi-
gated frequency and function of gdT-cells after allo-SCT in order to
assess their therapeutic potential.
Methods: PBMCs at time points within 3 months after allo-SCT
of 17 patients were sampled. CMV viral load was monitored by
PCR. Phenotype and frequency of gdT-cells and alpha beta T-cells
(abT-cells) were analyzed by flow cytometry. GdT-cells of 2 pa-
tients with CMV reactivation were isolated and expanded. Fre-
quency and clonality of Vd11, Vd21 and Vd31T cells were
measured with spectratyping. The reactivity against CMV infected
fibroblasts of Vd2- and Vd21T-cells was tested using an IFN-g
ELISPOT.
Results:We observed an increased expansion of Vd11T-cells after
allo-SCT in patients during CMV reactivation as assessed by flow
cytometry and spectratyping. Furthermore Vd11 but not Vd21T-
cells from these patients reacted against CMV infected fibroblasts.
Moreover, following pp65-reactive abT-cells in HLA-A21 patients
indicated that Vd11T cells precede an abT-cell response. Finally
Vd11T cells were able to induce antigen independent maturation
of dendritic cells (DC) via CD1c.
Conclusion: GdT-cells are present in patients after allo-SCT, have
the potential to eradicate CMV infected fibroblasts and possibly the
potential to spread an immune response to abT-cells via DC matu-
ration. This strongly supports the idea to explore gdT-cells as cell
population for immune interventions after allo-SCT.173
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A key parameter affecting the therapeutic potency of adoptive T
cell transfer is the extent to which infused cells persist and expand
in vivo. Ex vivo expanded CD81 effector T cells derived from
CD45RO1CD62L1 central memory (TCM) precursors are epige-
netically programmed to persist and revert to memory T cells fol-lowing adoptive transfer. TCM are a rare subpopulation of
lymphocytes in peripheral blood, therefore we sought to develop
a clinical-scale immunomagnetic purification method to isolate
CD81 TCM for subsequent genetic modification to express CD19-
specific chimeric antigen receptors (CAR). Using a two step process
by which monocytes, na€ıve and CD41T cells are first depleted from
PBMC, followed by positive selection of CD62L1 TCM, we have
found that CD81TCM can be enriched from 2-8% to. 80% purity.
Following isolation, CD81 TCM can be activated with CD3/CD28
Dynal beads, transduced two days later with cGMP grade self-inac-
tivating lentivirus (MOI 1.5), then expanded with 50U/ml IL-2 and
0.5ng/ml IL-15. This process results in the procurement of cell num-
bers for clinical use within 3-6 weeks without further ex vivo stimu-
lation (i.e., 1-3x109 final product from 7-15x106 CD81TCM). These
TCM -derived effector cell products (TE(CM)) are 80-90%CAR
1 and
exhibit CD19-specific cytolytic function and IFN-g production. Ad-
ditionally, these products consist of a broad repertoire of TE(CM)
based on TCR Vb usage, retain expression of central memory
markers such as CD62L/CD28, and, upon adoptive transfer into im-
munodeficient NOG mice, exhibit in vivo engraftment fitness in
a huIL-15 dependent manner. This process has undergone a series
of full scale qualification runs under cGMP and our group will be ap-
plying CD19-specific CD81 TE(CM) for post autologous HSCT
adoptive therapy of high risk lymphoma as an innovative strategy
to deliver engineered GVL effectors for eradication of minimal re-
sidual disease.174
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Electronic systems for physician orders have largely focused
on medications but orders for cellular products are also a poten-
tial source of communication errors that may affect patient
safety. As part of a quality improvement effort, we developed
and implemented an electronic order entry system for therapeu-
tic cellular products of various types. Biotherapy Order Entry
(BOE) was built to include three types of physician orders: 1)
cell collection, 2) cell processing and 3) product release for ad-
ministration. For each order type, electronic templates are
created based on requirements of specific treatment plans or
IRB-approved clinical research protocols. Each order set imports
patient demographics from the hospital registration system and
patient registration information from the Quality Assurance for
Clinical Trials (QACT) information system. Individual templates
for each treatment plan or research protocol are reviewed and
approved before activation and orders can only be placed after
consent to a treatment plan or protocol has been confirmed.
For example, template orders for collection of hematopoietic
stem cells specify cellular product type and the target number
(or range) of cells requested. Processing orders for hematopoietic
stem cells specify manufacturing steps such as CD34 selection,
cryopreservation or thawing and desired cell dose. Release orders
specify the cell type and cell dose needed for administration.
When cryopreserved products are available for administration,
physicians can select individual products for release. Since tem-
plates are specific for individual treatment plans or protocols,
physician order choices are restricted by the requirements of
the protocol each patient has been registered to. This system
was implemented in June 2010 after extensive in-house planning,
development, validation and end-user training. This quality im-
provement process gave us the opportunity to review and im-
prove the workflow processes in all areas (clinical, collections,
registration, processing, information management) related to cel-
lular therapy.
